


In the Claims:

1. (Previously Presented) A compound of formula (I)



wherein:

R is halogen or C₁₋₄ alkyl;

R₁ is hydrogen or C₁₋₄ alkyl;

R₂ is hydrogen, C₁₋₄ alkyl or R₂ together with R₃ represents C₃₋₇ cycloalkyl;

R₃ is hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl or C₃₋₆ alkenyl; or R₁ and R₃ together with nitrogen and carbon atom to which they are attached respectively represent a 5 to 6 membered heterocyclic group;

R₄ is trifluoromethyl, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethoxy or halogen;

R₅ is hydrogen and R₆ is NR₇R₈ or R₅ is NR₈R₉ and R₆ is hydrogen;

R₇ is hydrogen or C₁₋₄ alkyl or R₇ and R₈ together with nitrogen to which they are attached are a saturated 5 to 7 membered heterocyclic group containing oxygen;

R₈ is hydrogen, phenyl, C₃₋₇ cycloalkyl, (CH₂)_pC(O)NR₁₀R₁₁, a saturated 5 to 7 membered heterocyclic group containing 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen and optionally substituted by C₁₋₄ alkyl, S(O)₂C₁₋₄ alkyl or C(O)C₁₋₄ alkyl, a 5 membered heteroaryl group containing 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen and optionally substituted by C₁₋₄ alkyl S(O)₂C₁₋₄ alkyl or C(O)C₁₋₄ alkyl or R₈ represents a 6 membered heteroaryl group containing 1 to 3 nitrogen atoms and optionally substituted by C₁₋₄ alkyl, S(O)₂C₁₋₄ alkyl or C(O)C₁₋₄ alkyl; or R₈ is a C₁₋₆ alkyl group optionally substituted by one or two groups selected from fluorine, phenyl (optionally substituted by C₁₋₄ alkyl, C(O)C₁₋₄ alkyl or halogen), =O, C₃₋₇ cycloalkyl, hydroxy, amino, dimethylamino, aminocarbonyl, C₁₋₄ alkoxy or trifluoromethyl;

R₉ is hydrogen, C₁₋₄ alkyl or R₉ and R₈ together with nitrogen to which they are attached are a 5 to 7 membered heterocyclic group optionally containing another heteroatom selected from oxygen, sulphur and nitrogen and optionally substituted by one or two groups selected from C₁₋₄ alkyl, =O, S(O)₂C₁₋₄ alkyl, C(O)C₃₋₇ cycloalkyl or C(O)C₁₋₄ alkyl;

R₁₀ and R₁₁ are independently hydrogen or C₁₋₄ alkyl group;

X is a nitrogen atom and Y is CH or X represents CH and Y is nitrogen;

m is zero or an integer from 1 to 3;

n is an integer from 1 to 3;

p is zero, 1 or 2;

or a pharmaceutically acceptable salt or solvate thereof.

2. (Previously Presented) A compound as claimed in claim 1 wherein R₆ is NR₇R₈ and R₅ is hydrogen, Y is nitrogen and X is CH.

3. (Previously Presented) A compound as claimed in claim 1 wherein m is zero or an integer from 1 to 2.

4. (Previously Presented) A compound as claimed in claim 1 wherein R₁ is a methyl group.

5. (Previously Presented) A compound as claimed in claim 1 wherein R₂ is a hydrogen atom or a methyl group.

6. (Previously Presented) A compound as claimed in claim 1 wherein R₃ is a hydrogen atom or a methyl group.

7. (Previously Presented) A compound as claimed in claim 1 wherein R₄ is a trifluoromethyl group and/or halogen and n is 2.

8. (Previously Presented) A compound as claimed in claim 1 wherein R₅ is hydrogen, NH(C₃₋₇ cycloalkyl), NH(C₁₋₄alkylC₃₋₇ cycloalkyl), 1-piperazinyl(optionally substituted by one or two groups selected from C₁₋₄ alkyl, =O, S(O)₂C₁₋₄ alkyl,

C(O)C₃₋₇ cycloalkyl or C(O)C₁₋₄ alkyl; piperidyl (optionally substituted by one or two groups selected from C₁₋₄ alkyl, =O,) or morpholino.

9. (Previously Presented) A compound as claimed in claim 1 wherein R₆ is hydrogen, N(C₁₋₆alkyl)₂, NH(C₁₋₆alkyl), NH(CH₂)_pC(O)NR₁₀R₁₁ wherein p is 1 or 2 and R₉ and R₁₀ are independently hydrogen or methyl, NH(C₁₋₆ alkyltrifluoromethyl), NH(C₁₋₆alkylC₁₋₄alkoxy), NH(C₁₋₆alkylfluorine), N(C₁₋₆ alkyl)(C₁₋₆ alkylfluorine), NH(C₁₋₆ alkylphenyl), NH(C₃₋₇cycloalkyl), NH(piperidyl), NH (C₁₋₆ alkyl aminocarbonyl), NH(C₁₋₆ alkyl-1.3 dioxolan-yl) or morpholino.

10. (Currently Amended) A compound as claimed in claim 1 wherein R₆ is NR₇R₈ and R₅ is hydrogen, Y is nitrogen and X is CH or wherein R₆ is hydrogen and R₅ is NR₈R₉, Y is CH and X is nitrogen;
R₇ is hydrogen or methyl; R₈ is methyl, ethyl, dimethylpropyl, cyclopropyl, cyclobutyl, CH₂C(O)NH₂, piperidinyl, 1-methyl-piperidinyl, methyl substituted by a group selected from phenyl, cyclopropyl, 4-acetyl-piperazino, fluorine, methoxy, trifluoromethyl and 1.3 dioxolan-yl;
R₉ is hydrogen or methyl;
R₉ and R₈ together with nitrogen to which they are attached is 1-piperazinyl, acetyl-1-piperazinyl, morpholino;
R₇ and R₈ together with nitrogen to which they are attached is morpholino;
R is independently fluorine or methyl;
R₄ is trifluoromethyl and/or chlorine;
m is 1 or 2; and
n is 2.

11. (Previously Presented) A compound as claimed in claim 1 selected from :
4-(S)-Dimethylamino-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methanamide hydrochloride; 4-(S)-Dimethylamino-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methanamide hydrochloride; 4-(S)-(2-Fluoroethyl)-amino-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methanamide hydrochloride; and 4-(S)-(2-Fluoro-



ethylamino)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methanamide hydrochloride.

12-14. (Canceled).

15. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 1 in a mixture with one or more pharmaceutically acceptable carriers or excipients.

16. (Canceled).

17. (Previously Presented) A process for the preparation of a compound as claimed claim 1 comprising reductive N-alkylation of a compound of formula (II), wherein R_{12} is =O and R_{13} is hydrogen or R_{12} is hydrogen and R_{13} is =O



with an amine derivative (III) or a salt thereof in the presence of a suitable metal reducing agent, followed where necessary or desired by one or more of the following steps:

- i) removing any protecting group;
- ii) isolating the compound as a salt or a solvate thereof;
- iii) separating the compound into enantiomers thereof.

18. (Previously Presented) A compound as claimed in claim 1, wherein R_6 is hydrogen and R_5 is NR_8R_9 , Y is CH and X is nitrogen.

19. (Previously Presented) A method for the treatment of a condition mediated by a tachykinin in a mammal comprising administering an effective amount of a compound as claimed in claim 1.
20. (Previously Presented) The method as claimed in claim 19, wherein said tachykinin is substance P.
21. (Previously Presented) The method as claimed in claim 19, wherein said mammal is man.
22. (Previously Presented) A method for the treatment of a CNS disorder in a man comprising administering an effective amount of a compound as claimed in claim 1.
23. (Previously Presented) The method according to claim 22, wherein said CNS disorder is selected from depressive states and anxiety.
24. (Previously Presented) A method for the treatment of emesis in a mammal comprising administering an effective amount of a compound as claimed in claim 1.